HelioLiver LDT now available to order through Quest Diagnostics
Business team celebrating an award
News & Media

Helio Health Honored with Second Consecutive MedTech Breakthrough Award

Award May 5, 2022 5 min read MedTech Breakthrough
Share

HelioLiver™ was named Best New Biopsy Technology Solution in the sixth annual MedTech Breakthrough Awards — Helio’s second consecutive MedTech Breakthrough win.

MedTech Breakthrough 2022
MedTech Breakthrough 2022
Best New Technology Solution – Biopsy

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies.

IRVINE, Calif., May 5, 2022 /PRNewswire/ — Helio Health (“Helio”), an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that HelioLiver™ has been recognized as “Best New Biopsy Technology Solution” in the sixth annual MedTech Breakthrough Awards program, which recognizes the top companies, technologies and products in the global health and medical technology market. This marks the second consecutive year that Helio has been recognized by MedTech Breakthrough – in 2021, Helio was awarded “Best New Technology Solution for Diagnostics.”

Launched in December 2021, HelioLiver is an easy-to-use blood test that examines novel biomarkers to detect hepatocellular carcinoma (HCC) early, while curative treatment is still an option. To improve the accuracy of detecting HCC, HelioLiver takes a multi-analyte approach to evaluate cell free DNA (cfDNA) methylation patterns across nearly 30 genes and measures 3 key proteins. Recent data shows HelioLiver outperformed two other clinically available tests in detecting early-stage and overall HCC. HelioLiver has demonstrated high specificity (91%) and high sensitivity (76%) in detecting early-stage (stage I and II) HCC.

In addition to its strong clinical performance, HelioLiver is convenient for patients and providers alike, requiring only a simple blood draw that can be conducted during a routine check-up, to make it easy for people at high risk for cancer to stay on top of their surveillance plans.

“We are thrilled to win another MedTech Breakthrough award recognizing HelioLiver. Helio has developed an advanced platform technology that can revolutionize the future of early cancer detection. We are committed to continuing to advance next-generation blood-based cancer detection tools to ensure wide access to tests that can detect cancer at its earliest stages without the need for invasive and inconvenient procedures such as mammograms and colonoscopies. Our patient-first commitment aims to remove barriers to testing and ultimately improve patient outcomes, while reducing cost burden across the healthcare system.”

JLJustin Chen LiChief Executive Officer, Helio Health

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize innovation, hard work and success in a range of health and medical technology categories. This year’s program attracted more than 3,900 nominations from over 15 different countries throughout the world.

“Early detection of liver cancer is critical to successful outcomes with a survival rate that increases 13-fold when caught in early versus late stages, when curative options may still be available. Unfortunately, more than half of HCC cases are diagnosed late when the cancer has already progressed, due to low surveillance rates and delays in follow-up. By leveraging its platform technology that combines the identification of signature biomarkers complemented with DNA methylation, Helio has the potential to change the entire paradigm of cancer diagnostics by enabling early cancer detection. Congratulations on another MedTech Breakthrough win with ‘Best New Biopsy Technology Solution.’”

JJJames JohnsonManaging Director, MedTech Breakthrough

About Helio Health

Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company’s mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio’s AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests. Helio’s development program is focused on liver, colon, breast and lung cancer. Helio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN.

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. For more information visit MedTechBreakthrough.com.

Read the Press Release

SOURCE Helio Health. View source version on PR Newswire.

Related Articles

More from Helio Genomics

NewsMay 12, 2026

HelioLiver Expands Access Through Quest

Helio broadens access to HelioLiver through Quest Diagnostics’ nationwide network of patient service centers.

Read more
NewsMay 8, 2026

Collaborating with the Rural Health Transformation Collaborative, Co-Chaired by Microsoft

Helio joins the Rural Health Transformation Collaborative, co-chaired by Microsoft, to expand rural early detection.

Read more
VoicesMay 6, 2026

Bharat Tewarie: Giving Patients a “Real Fighting Chance” Against Liver Cancer

Helio’s CEO reflects on the landmark CLiMB study and what earlier liver cancer detection means for patients.

Read more